Objective. The main of this research was to evaluate the clinicopathological characteristics of diffuse large B-cell lymphoma, no other specification (DLBCL, NOS) in a cohort of Peruvian patients diagnosed between 2005 and 2009. Methods. Seventy-two cases diagnosed with DLBCL, NOS, were studied at the National Institute of Neoplastic Diseases. Clinicopathological characteristics were evaluated and overall survival (OS) and other clinical parameters were compared according to cell of origin, Epstein-Barr virus (EBV) infection, and immunohistochemical (IHC) expression of MYC and BCL2. Results. There were 54 % women and 46 % men, with an average age of 65 years. 76 % were nodal, the majority cervical, and 24 % extranodal, with the stomach being the most affected site. The most frequent stages were II (35 %) and III (29 %), the majority with medium-high and high IPI. Histologically, almost a...

Objective. To evaluate the clinicopathological characteristics of diffuse large B-cell lymphoma, not otherwise specified (LCBGD, NOS), in a cohort of peruvian patients. Methods. Seventy-two cases with a diagnosis of LCBGD, NOS, were studied at the INEN. Clinicopathological characteristics, overall survival (OS) and other clinical parameters were evaluated according to origin cell, Epstein-Barr virus infection (EBER), and the immunohistochemical expression (IHC) of MYC and BCL2. Results. There were 54% women and 46% men, with an average age of 65 years. 76% were ganglionic, the majority cervical location and 24% extranodal, the stomach being the most affected. The most frequent stages were II (35%) and III (29%), the majority with medium-high and high IPI. Histologically, almost all cases had centroblastic and immunoblastic morphology. There was a similar proportion of cases with germinal...

In recent years, the rapid technological development and the better knowledge of genetic and molecular aspects in medicine have allowed a better approach to understand, diagnose and treat various oncological diseases. Regarding lung carcinoma, there has been a remarkable evolution from the first classifications, which were purely morphological, to the last one issued in 2015. This last classification includes histological, immunophenotypic, molecular genetics, clinical and radiological information, which allows a better evaluation and therapeutic management of these patients. In the present article, the first classifications of lung carcinoma to the last one are reviewed, and the most relevant changes and the importance of the molecular genetics findings are examined for a better clinical and therapeutic approach.